- Home
- ENTA vs PLX Comparison
ENTA vs PLX Comparison
Compare ENTA & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- PLX
- Stock Information
- Founded
- ENTA 1995
- PLX 1993
- Country
- ENTA United States
- PLX Israel
- Employees
- ENTA N/A
- PLX N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ENTA Health Care
- PLX Health Care
- Exchange
- ENTA Nasdaq
- PLX Nasdaq
- Market Cap
- ENTA 154.0M
- PLX 160.2M
- IPO Year
- ENTA 2013
- PLX 1998
- Fundamental
- Price
- ENTA $5.59
- PLX $2.57
- Analyst Decision
- ENTA Buy
- PLX Strong Buy
- Analyst Count
- ENTA 4
- PLX 1
- Target Price
- ENTA $17.25
- PLX $15.00
- AVG Volume (30 Days)
- ENTA 228.9K
- PLX 791.9K
- Earning Date
- ENTA 05-05-2025
- PLX 03-17-2025
- Dividend Yield
- ENTA N/A
- PLX N/A
- EPS Growth
- ENTA N/A
- PLX N/A
- EPS
- ENTA N/A
- PLX 0.04
- Revenue
- ENTA $66,590,999.00
- PLX $53,399,000.00
- Revenue This Year
- ENTA N/A
- PLX $67.17
- Revenue Next Year
- ENTA N/A
- PLX $55.31
- P/E Ratio
- ENTA N/A
- PLX $69.84
- Revenue Growth
- ENTA N/A
- PLX N/A
- 52 Week Low
- ENTA $4.71
- PLX $0.82
- 52 Week High
- ENTA $17.80
- PLX $2.76
- Technical
- Relative Strength Index (RSI)
- ENTA 31.66
- PLX 58.33
- Support Level
- ENTA $5.65
- PLX $2.24
- Resistance Level
- ENTA $5.96
- PLX $2.62
- Average True Range (ATR)
- ENTA 0.36
- PLX 0.15
- MACD
- ENTA -0.15
- PLX 0.03
- Stochastic Oscillator
- ENTA 4.77
- PLX 82.08
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.